Markets

AbbVie Extends Deal With Voyager to Make Parkinson's Drugs

AbbVie, Inc.ABBV announced an expansion of its global strategic collaboration and option agreement with small biotech Voyager Therapeutics, Inc. VYGR to develop potential gene therapies for Parkinson's disease (PD) and other synucleinopathies.

Per the deal, Voyager will develop vectorized antibodies targeting pathological species of alpha-synuclein. An abnormal accumulation of misfolded alpha-synuclein protein eventually leads to the formation of protein deposits and progressive neurodegeneration in patients with PD and other synucleinopathies.

Per the deal, Voyager will develop vectorized antibodies in preclinical stage, after which AbbVie has an option to in-license the vectorized alpha-synuclein antibody program for further clinical development.

Voyager is entitled to receive $65 million upfront from AbbVie and up to $245 million in preclinical and phase I option payments. Meanwhile, Voyager will also be entitled to potential development, regulatory, and commercial milestone payments of up to $728 million and royalties on future sales.

Last year, AbbVie signed a collaboration with Voyager to develop potential new treatments for Alzheimer's disease and other tau-related neurodegenerative diseases.

Shares of Voyager were up almost 23% on announcement of the deal with AbbVie.

AbbVie has always been actively pursuing partnership deals and collaborations for candidates across several therapeutic areas including oncology, immunology, neuroscience, and infectious diseases. Some partners include Roche RHHBY , J&J JNJ and Boehringer Ingelheim among others. We believe the company will continue pursuing deals like the one with Voyager to grow its pipeline.

AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

This Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world - and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Roche Holding AG (RHHBY): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Voyager Therapeutics, Inc. (VYGR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

RHHBY JNJ VYGR ABBV

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More